Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a peptide drug shield the hearts of ICU patients?

NCT ID NCT06117046

Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing whether cardiomyopeptidin, an intravenous drug, can protect the heart muscle of ICU patients who have signs of cardiac injury but no diagnosed heart disease. The trial enrolls 234 adults with high troponin levels during their ICU stay. Participants receive either cardiomyopeptidin or a saline infusion for three days, and researchers track major cardiac events, mortality, and heart function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cardiomyopeptidin, an intravenous drug given for three days
What this could lead to
If it works, cardiomyopeptidin could become a way to protect heart muscle in ICU patients who develop cardiac injury from other illnesses.
What could go wrong
This is a small, single-center pilot study, so any signal may not hold up in larger trials. Cardiomyopeptidin is not proven for this use, and intravenous drugs carry risks such as allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

234 people

The number who actually took part.

Started

Feb 2023

Finished

Nov 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years old 2. The high-sensitive troponin T index was higher than the normal value during ICU hospitalization 3. Obtain the informed consent of the subject or legal agent Exclusion Criteria: 1. Patients who are expected to die within 48 hours of ICU admission 2. previous diagnosis of acute coronary syndrome, chronic cardiomyopathy, pulmonary heart disease, acute myocarditis, pericardial tamponade and other diseases that have been confirmed to cause myocardial injury 3. cardiopulmonary resuscitation and/or electrical defibrillation before admission 4. patients with acute ischemic stroke 5. patients with stage 5 chronic kidney disease 6. during pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ICU are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ICU Myocardial injury

Contacts and locations

Locations

  • Southern medical university Nanfang hospital

    Guangzhou, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.